These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28443355)

  • 1. Investigational dopamine antagonists for the treatment of schizophrenia.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.
    Rao NP; Remington G
    Expert Opin Investig Drugs; 2013 Jul; 22(7):881-94. PubMed ID: 23639138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.
    Rao NP; Remington G
    Expert Opin Pharmacother; 2014 Feb; 15(3):373-83. PubMed ID: 24354659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor heteromers: biasing antipsychotics.
    Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F
    Future Med Chem; 2018 Dec; 10(23):2675-2677. PubMed ID: 30518245
    [No Abstract]   [Full Text] [Related]  

  • 7. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for schizophrenia: an update.
    Köster LS; Carbon M; Correll CU
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):511-31. PubMed ID: 25234340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist.
    Bristow LJ; Kramer MS; Kulagowski J; Patel S; Ragan CI; Seabrook GR
    Trends Pharmacol Sci; 1997 Jun; 18(6):186-8. PubMed ID: 9226994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Functional role of dopamine D4 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):13-20. PubMed ID: 15027326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinued drugs in 2005: schizophrenia drugs.
    Kerwin R
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1487-95. PubMed ID: 17107275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of antipsychotic drugs: focus on therapeutic and adverse effects.
    Werner FM; Coveñas R
    Expert Opin Drug Saf; 2014 Aug; 13(8):1031-42. PubMed ID: 24975932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine treatment of schizophrenia.
    Pickar D; Hsiao JK
    JAMA; 1995 Sep; 274(12):981-3. PubMed ID: 7674530
    [No Abstract]   [Full Text] [Related]  

  • 16. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The search for novel antipsychotics: pharmacological and molecular targets.
    Sanger DJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.